Efficacy and safety of catheter-based biatrial linear ablation for very long-standing persistent atrial fibrillation: a prospective observational registry

Asan Medical Center0 个研究点目标入组 69 人开始时间: 待定最近更新: 2023年9月18日

试验速览

暂无简介。

•Adults aged between 18-85
•Diagnosed with persistent atrial fibrillation lasting for more than 7 days, as confirmed by a 12-lead ECG, Holter monitor, event recorder, or exercise stress test
•Patients who have been diagnosed with atrial fibrillation for more than 3 years but less than 10 years
•Resistant to or having side effects from one or more class I or III antiarrhythmic drugs
•Patients receiving their first (de-novo) catheter ablation procedure for atrial fibrillation

•Refusal to participate in the research
•BMI = 35kg/m^2
•Intracardiac thrombus
•Contraindications to anticoagulant therapy
•History of surgical or interventional treatment for atrial fibrillation
•Severe valvular heart disease, aortic stenosis, or mechanical prosthetic valve
•Anteroposterior diameter of the left atrium of 60mm or more
•NYHA class IV heart failure
•Thoracic surgery within the last 3 months
•Planned thoracic surgery within the next 3 months
•End-stage heart failure or severe renal failure (estimated glomerular filtration rate [MDRD method] < 30mL/min/1.73m)
•Pregnant or breastfeeding women
•Acute coronary syndrome within the last 3 months
•Co-morbidity (such as ongoing cancer treatment) with expected survival of less than 1 year

发起方